Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $5.13B
• Dividend Yield: N/A
• Average Volume (3M): 2.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: -81.18%
• EPS Growth: -69.19%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 90,950,424
• 10 Day Avg. Volume: 2,245,772
• 30 Day Avg. Volume: 2,553,212
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $81.44
• Price Target Upside: 42.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -6.32
• Revenue Forecast (FY): $27.09M

• Rating: 41 Neutral
• Price Target: $54.00 ▼(-5.25% Downside)

Crispr Therapeutics AG's overall stock score is primarily impacted by its challenging financial performance, with negative profitability and cash flow metrics. The technical analysis indicates bearish momentum, and the valuation reflects the company's unprofitability. The absence of earnings call and corporate events data limits additional insights.

Positive Factors

Innovative Gene Editing Platform

The development of the SyNTase platform for gene editing represents a significant advancement in CRISPR's technology, potentially leading to new treatments for genetic disorders. This innovation could enhance the company's competitive edge in the biotechnology sector.

Strategic Collaborations

Strategic partnerships with established pharmaceutical companies provide Crispr Therapeutics with financial resources and enhance its R&D capabilities. These collaborations can accelerate product development and commercialization, supporting long-term revenue growth.

Advancement in Clinical Trials

Progress in clinical trials, such as the dosing of the first patient in a Phase 2 trial, indicates advancement in CRISPR's pipeline. Successful trials can lead to new product approvals and market entry, driving future revenue and market position.

Negative Factors

Negative Profitability

Crispr Therapeutics' ongoing negative profitability poses a challenge to its financial stability. Sustained losses can limit reinvestment in R&D and expansion, potentially impacting long-term growth and competitive positioning.

Revenue Decline

A significant decline in revenue growth indicates challenges in generating sales from existing products or collaborations. This trend could hinder the company's ability to fund ongoing R&D and affect its market competitiveness.

Cash Flow Challenges

Negative cash flows highlight sustainability concerns, as the company may struggle to cover operational expenses without external funding. This situation could limit strategic investments and slow down product development.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics generates revenue through a combination of product sales, research collaborations, and licensing agreements. The company is primarily focused on advancing its gene-editing therapies through clinical trials, which, upon successful commercialization, could lead to significant sales revenue. In addition, Crispr Therapeutics has established partnerships with major pharmaceutical companies, such as Vertex Pharmaceuticals, which contribute to its financial resources through upfront payments, milestone payments based on clinical and regulatory progress, and royalty payments on future sales of products developed through these collaborations. These collaborations not only provide funding but also enhance the company's capabilities in research and development, thus contributing to its potential earnings.

Crispr Therapeutics AG Financial Statement Overview

Summary

Crispr Therapeutics AG faces significant financial challenges, with negative profitability and cash flow metrics. Despite manageable leverage, the company struggles with generating positive returns and cash flows, likely due to high R&D costs typical in the biotechnology industry.

Income Statement

Crispr Therapeutics AG has experienced significant volatility in its revenue and profit margins. The TTM data shows a slight revenue growth, but the company is struggling with negative gross and net profit margins, indicating high costs relative to revenue. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Despite a past year of strong revenue growth, recent trends show declining profitability.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage. However, the return on equity is negative, indicating that the company is not generating profit from its equity base. The equity ratio is stable, reflecting a solid asset base, but the negative ROE highlights profitability issues.

Cash Flow

Crispr Therapeutics AG's cash flow statement reveals negative operating and free cash flows, which are concerning for sustainability. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is aligned with reported losses. However, the negative growth in free cash flow and operating cash flow coverage ratio suggests ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	37.36M	35.00M	371.21M	436.00K	913.08M	543.00K
Gross Profit	-81.06M	-75.25M	240.96M	-109.81M	895.13M	-268.86M
EBITDA	-511.48M	-447.31M	-202.70M	-648.99M	391.48M	-345.25M
Net Income	-467.80M	-366.25M	-153.61M	-650.17M	377.66M	-348.87M
Balance Sheet
Total Assets	2.03B	2.24B	2.23B	2.24B	2.75B	1.83B
Cash, Cash Equivalents and Short-Term Investments	1.72B	1.90B	1.69B	1.82B	2.38B	1.69B
Total Debt	215.45M	223.69M	238.63M	244.02M	225.03M	61.43M
Total Liabilities	318.59M	309.95M	346.77M	367.58M	352.42M	163.73M
Stockholders Equity	1.71B	1.93B	1.88B	1.88B	2.40B	1.66B
Cash Flow
Free Cash Flow	-325.57M	-144.68M	-272.35M	-532.93M	457.27M	-256.72M
Operating Cash Flow	-324.77M	-142.77M	-260.38M	-495.74M	538.97M	-238.37M
Investing Cash Flow	-5.55M	-280.48M	374.65M	-258.65M	-1.04B	-541.17M
Financing Cash Flow	39.36M	331.98M	62.66M	38.59M	250.94M	1.02B

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 56.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Negative. The current price of 56.99 is below the 20-day moving average (MA) of 65.86, below the 50-day MA of 62.88, and above the 200-day MA of 49.52, indicating a neutral trend. The MACD of -2.00 indicates Positive momentum. The RSI at 37.03 is Neutral, neither overbought nor oversold. The STOCH value of 11.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	83 Outperform	$1.77B	9.87	25.93%	―	21.13%	50.86%
ARQT	59 Neutral	$2.94B	―	-28.17%	―	129.21%	80.35%
VERV	52 Neutral	―	―	―	―	271.44%	26.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NTLA	50 Neutral	$1.31B	―	-56.95%	―	14.99%	14.42%
BEAM	46 Neutral	$2.31B	―	-47.19%	―	-84.07%	-157.71%
CRSP	41 Neutral	$5.13B	―	-25.34%	―	-81.18%	-69.19%

Crispr Therapeutics AG Corporate Events

Crispr Therapeutics’ Long-term Study on CAR T Therapies: A Market Game Changer?

Study Overview: The clinical study titled A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies aims to evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies in subjects with hematologic and solid malignancies. This study is significant as it seeks to provide insights into the durability and safety of these innovative therapies over an extended period.

Crispr Therapeutics AG Files $600M Share Offering

On October 15, 2025, CRISPR Therapeutics AG announced the filing of a prospectus supplement with the SEC to offer and sell additional common shares worth up to $600 million through Jefferies LLC. This move aligns with the company’s strategic financial initiatives, potentially impacting its market position and stakeholder interests by providing additional capital for its operations and growth.

The most recent analyst rating on (CRSP) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Crispr Therapeutics’ Long-term Study on CAR T Therapies: A Potential Game Changer

Study Overview: The study titled A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies aims to assess the long-term safety and efficacy of CRISPR CAR T cellular therapies. This observational study is significant as it seeks to gather data on the long-term outcomes of patients with hematological and solid malignancies who have undergone these innovative treatments.

Crispr Therapeutics’ CTX112 Study: A New Frontier in Autoimmune Disease Treatment

Study Overview: The clinical study titled A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease aims to assess the safety and initial effectiveness of CTX112 in adults suffering from challenging autoimmune conditions like systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy. This study is significant as it explores innovative gene-editing technology to potentially transform treatment options for these refractory diseases.

Crispr Therapeutics’ CTX112 Study: A Promising Step in Autoimmune Disease Treatment

Study Overview: The clinical study titled ‘A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease’ aims to assess the safety and initial effectiveness of CTX112. This study is significant as it targets challenging autoimmune diseases like systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy, offering hope for patients with limited treatment options.

CRISPR Therapeutics Reports Q2 2025 Progress and Financials

CRISPR Therapeutics is a biopharmaceutical company specializing in gene-based medicines for serious diseases, leveraging the CRISPR/Cas9 technology to develop transformative therapies across various medical fields.